INCB 053914

Drug Profile

INCB 053914

Alternative Names: INCB-053914; INCB-53914

Latest Information Update: 29 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action PIM3 protein inhibitors; Proto oncogene proteins c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • Preclinical Acute myeloid leukaemia; Multiple myeloma

Most Recent Events

  • 09 Dec 2017 Interim adverse events, pharmacokinetics and pharmacodynamics data from a phase I/II trial in Cancer presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)
  • 02 Apr 2017 Pharmacodynamics data from a preclinical trial in Diffuse large B cell lymphoma presented at the 108th Annual Meeting of the American Association for Cancer Research(AACR-2017)
  • 01 Oct 2015 Phase-I/II clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02587598)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top